Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 162 clinical trials
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer

in patients presenting with locally advanced breast cancer.

sentinel lymph node biopsy
axillary lymph node dissection
advanced breast cancer
locally advanced breast cancer
sentinel node
  • 30 views
  • 24 Jan, 2021
  • 8 locations
FASN Inhibitor TVB-2640 Paclitaxel and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer

This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body. FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell …

biomarker analysis
platelet count
her2 positive breast cancer
hormone therapy
chemotherapy regimen
  • 35 views
  • 25 Jan, 2021
  • 3 locations
CDK4/6-inhibitor or Chemotherapy in Combination With ENDOcrine Therapy for Advanced Breast Cancer / KENDO

Prospective, open label, multicenter, group sequential response adaptive randomized phase 2 study, comparing two treatments for locally advanced or metastatic luminal breast cancer: Arm A: concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor (palbociclib, ribociclib or abemaciclib) plus endocrine therapy (aromatase inhibitor [AI] or fulvestrant) Arm B: chemotherapy plus endocrine therapy (AI …

progesterone receptor
abemaciclib
hormone therapy
capecitabine
her2/neu-negative breast cancer
  • 15 views
  • 24 Jan, 2021
  • 20 locations
Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Trastuzumab resistance, which is a common therapeutic challenge in HER2 positive metastatic breast cancer, is not fully understood. Pyrotinib is an oral tyrosine kinase inhibitor targeting EGFR, HER-2 and HER-4 receptors. More general inhibition of ErbB family with pyrotinib could provide additional benefit. This study is designed to evaluate the …

measurable disease
liver metastasis
trastuzumab
hormone therapy
capecitabine
  • 4 views
  • 23 Jan, 2021
  • 1 location
Study of DS-8201a an Antibody Drug Conjugate for Advanced Breast Cancer Patients With Biomarkers Analysis

Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.

progesterone receptor
stage iv breast cancer
hormone therapy
capecitabine
renal function test
  • 6 views
  • 25 Jan, 2021
  • 28 locations
Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

A phase II clinical trial designed to test the effect of combining endocrinal therapy (Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of female breast cancer with ER positive disease.

tamoxifen
hormone therapy
female breast cancer
capecitabine
erbb2
  • 0 views
  • 26 Jan, 2021
  • 1 location
Safety Pharmacodynamics Pharmacokinetics and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

advanced breast cancer (ABC) of any subtype. The trial will enroll up to 45 patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 with any breast cancer

breast adenocarcinoma
measurable disease
mammogram
paclitaxel
erbb2
  • 12 views
  • 29 Jan, 2021
  • 3 locations
Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention.

The LIBERATE intervention is a multi-component self-management, symptom monitoring and signposting website tailored to the supportive needs of women living with secondary breast cancer. Overall, this intervention aims to improve quality of life among this growing group of patients through targeted, tailored and accessible information and support. This randomised waiting …

advanced breast cancer
breast cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer

HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase (p110). In preclinical studies, it demonstrated strong activity against PI3K p110 in vitro and in vivo, and inhibited tumor cell growth. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity …

  • 0 views
  • 26 Jan, 2021
  • 3 locations
A Study of a New Drug Combination Copanlisib and Fulvestrant in Advanced Breast Cancer

This phase I/II trial studies the side effects and how well copanlisib works when given together with fulvestrant in treating patients with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer that has spread to other places in the body (advanced) and progressing after …

  • 0 views
  • 07 Mar, 2021
  • 1 location